We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Medgenics | MEDU | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 392.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 392.50 | 392.50 |
| Top Posts |
|---|
Posted at 27/3/2014 08:40 by fanboy1 Kalinit/CountSVS transferred mine from MEDG to MEDU free of charge. However I made the request after having held for a year (which was apparantly a condition) and back in October. It actually took until around mid February for them to appear in my online account as MEDU. I just rang up and asked. |
Posted at 27/3/2014 06:09 by kalinit Hi Count ChrisI have some with Self trade - they are forcing me to sell as they no longer settle on CREST. SIPP centre will transer it to the MDGN ticker without charge. TDW will also allow me to transfer MEDU to them and they will transer to MDGN but there may be a charge. Not sure what other peoples brokers are doing - anyone else can help Count Chris. It is really poor timing doing it just before what we hope are good results and the new trial. |
Posted at 03/3/2014 12:02 by 237gmoney Also why publish the RNS on MEDG but not on MEDU? very odd. Once again two fingers up to all small shareholders. very poor if you ask me. |
Posted at 14/9/2013 20:12 by fanboy1 Got to agree. Can anyone help with what the current valuation of this company actually is? Bit confused with the MEDU, MEDG, and MDGN. |
Posted at 16/7/2013 17:53 by buywell2 For the attention of jimmytass ..... XEN poster about MEDU |
Posted at 09/7/2013 14:35 by 237gmoney Great news today before the company present at the JMP Healthcare conference tomorrow. Not much has happened over tha last month and hopefully this is the start of more positive newsflow. Still awaiting news of the US Clinical trials so a JV or partnership deal should be announced shortly. Looking forward to the presentation tomorrow as well for an update on recent progress. Medgenics Inc $1.9 Million Grant Awarded from the Israeli OCS RNS Number : 8940I Medgenics Inc 09 July 2013 Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 6.7 million (approximately USD 1.9 million), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. The grant will be used to cover R&D expenses for the 12-month period from December 2012 through November 2013 to support further research and clinical development of the Company's proprietary tissue-based Biopump(TM) platform technology with respect to the treatment of anemia and hepatitis. The OCS awards grants to companies from various industries in Israel to foster technological innovations. Recipient selections are based on multiple criteria including the uniqueness of a company's technology, and the potential market it addresses, plus the robustness of the company's business including financial position, R&D capabilities and management experience. Under the terms of the OCS grant, MMI will repay the grant in full, plus interest, through royalties on revenue received from commercializing the developed technology. The payment of royalties is contingent on such revenues and, in the absence of such revenues, no royalty payments to the OCS are required. "We are delighted to have been selected to receive this non-dilutive funding from the Israeli OCS and appreciate the continued support. This is our seventh consecutive grant from the Israeli OCS. These grants have been instrumental in furthering the development of our technology and support us in advancing our clinical trials in the United States and Israel," stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics. |
Posted at 25/4/2013 15:13 by 237gmoney Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis PatientsData will be used to support Phase II trial in U.S. MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Apr. 25, 2013-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinical trial in Israel of EPODURE Biopumps to treat anemia in patients on dialysis with end-stage renal disease ("ESRD"). Each of the four patients had been receiving routine EPO injections with each dialysis session until his or her EPODURE Biopumps were administered by subcutaneous implantation. Initial and on-going experience to date in ESRD patients is in line with observations from the Company's prior Phase I/II study in anemic pre-dialysis patients with chronic kidney disease ("CKD"). To date, there have not been any procedure or drug related serious adverse events. Thus far in this single treatment study, each patient has received a single administration of EPODURE Biopumps, measured to produce between 19 to 51 IU EPO per kg per day, in place of the serial injections of EPO or ESA the patient had been receiving with each dialysis session. Following the administration of EPODURE Biopumps, the hemoglobin in these patients remained in the desired 9-11 g/dl range for approximately 2-4 months, without needing any EPO or other ESA injections. Notably, at no point following EPODURE treatment did the concentration of EPO in the serum of the patients exceed the typical normal range and always remained under 100 mU/ml. As the first study with EPODURE Biopumps in ESRD patients on dialysis, this Phase IIa study is testing administration techniques and dosing to determine how long a single treatment using EPODURE Biopumps can replace the periodic injections of EPO or other erythropoietic stimulating agents ("ESAs") currently used in the standard care of such patients, while maintaining the patient's hemoglobin within the desired range. The current standard of care for ESRD patients on dialysis involves EPO or ESA injections with each dialysis session, which is typically three times per week. Each injection is short-lived, typically causing an extreme transient elevation of EPO in the patient's blood to levels of several thousand milliUnits/ml, typically 10-100 times the normal physiological levels, followed by a decline to ineffective levels within a few days, so the patient may not have sufficient EPO or ESA until the next injection. The high transient levels of EPO in the blood are a source of potential safety concern to many medical experts as well as to the U.S. Food and Drug Administration ("FDA"), and is in marked contrast with the normal EPO levels maintained with EPODURE, as reported above. "These preliminary data are encouraging and we believe they will be valuable as we move forward with plans to implement a larger Phase II trial in the U.S. in the second half of 2013. When EPODURE reaches routine clinical use, we believe the ability to titrate the dose to reach the most effective dosing level based on the patient's early hemoglobin response could further extend the duration of hemoglobin maintenance," stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics. "EPODURE Biopumps aim to provide a cost-effective way to maintain hemoglobin within a target range in anemic patients by providing sustained delivery of EPO within the normal physiological range, while avoiding the extreme elevations seen with repeat injections. We believe that EPODURE could improve the safety and efficacy of anemia treatments while enhancing patient quality of life by providing a more reliable treatment that reduces or eliminates the need for frequent EPO or ESA injections, and also could provide clear cost benefits to payers," added Dr. Pearlman. |
Posted at 22/4/2013 14:25 by 237gmoney Good news out of a new patent or at least an expansion of an existing patent.Medgenics Receives Notice of Allowance from the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic Proteins MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Apr. 22, 2013-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the United States Patent and Trademark Office has issued a Notice of Allowance of claims that expand the Company's scope of patent coverage for additional therapeutic proteins. The claims in the patent are directed to a dermal Biopump expressing at least one recombinant gene product from any of the following: growth hormone, interferon beta, insulin, PDGF-BB, interleukin-1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin-10 (IL-10) and G-CSF. These claims, combined with the prior grant of patents for genetically modified dermal micro-organ expression of erythropoietin and interferon alpha, broaden Medgenics' scope of intellectual property in the field of genetically modified dermal micro-organs. Upon the issuance of this patent, Medgenics' global patent portfolio will include 45 patents granted, with 79 patent applications pending. Medgenics believes its approach to protein therapy will have multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins. Medgenics' technologies target a range of clinical indications within the global protein therapy market, which is forecast to reach $143 billion in 2015. "With this allowance we have further broadened the universe of therapeutic proteins that can be delivered through our Biopump platform technology. We continue to build the value of our intellectual property worldwide with the knowledge that new therapeutic areas will be covered by our patent portfolio," stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics. |
Posted at 02/4/2013 11:53 by 237gmoney Also today the spread in MEDG has come down in line with MEDU so they are now the same price.One of the resolutions in the AGM is to increase the Stock plan for employees by 1.7m shares. This will increase the available stock option to 2.5m for employees going forward. The Board of directors certainly know how to look after themselves. But I don't see this a bad thing as long as the share price increases. The directors will certainly do all they can to make this happen. |
Posted at 20/3/2013 10:18 by opaldouglas Gmoney/sicilian,Thanks for your swift responses, I actually came across MEDU at a proactive event last year and have been keeping tabs ever since. With near £20M in the bank and a market cap of circa £8M things look interesting, I must admit that I'm not particularly clued up with pharmaceuticals stocks in general so I find it hard to compare with comparable stocks. Do you happen to know how many shares are in issue (fully diluted)? OD |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
